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Abstract
The American University in Cairo
The Effect of Adding Radiotherapy to The Administrated Chemotherapy on
Infants Gut Microbiome
Nourhan Elsahly
Dr. Ahmed Moustafa
Dr. Tamer Salem
Dr. Mohamed Saad Zaghloul

The gut microbiota has been described as the forgotten organ owing to
its important roles in the human body, that includes but not limited to:
digestion, immunity, homeostasis and response to some drugs such as,
chemotherapy and immunotherapy. Its role has been also described in
reflection to radiotherapy and associated gastrointestinal injuries,
where dysbiosis and its associated side effects could be the driving
force for dose determination or the complete suspension of the
treatment plan. Linking the gut microbiota alterations to different
cancer treatment protocols is not easy, especially in humans. However,
enormous effort was exerted to understand this complex relationship.
In the current study, we described the gut microbiota dysbiosis in
infant sarcoma patients with regards to radiotherapy and antibiotics.
Fecal samples were collected as a source of microbial DNA for which
the gene encoding for 16S rRNA was sequenced, targeting V3-V5
regions. Two of the three patients understudy had experienced an
increase in alpha diversity post treatment. Although phylum
Firmicutes overall relative abundance was generally decreasing, six of
its taxa increased in all patients. Our results indicate the possibility of
radiosensitivity for the elevated taxa. Further studies are needed to
describe the extent of radiosensitivity with regards to antibiotic
resistance.
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Chapter 1: Literature Review
The terms Microbiome and Metagenome are rapidly evolving and
grasping more attention nowadays. Metagenome refers to the study of samples
derived from an environment. While Microbiome refers to collection of
microorganisms living in a specific environment (Stern et al., 2012). The
human body includes different environments where the microbes can reside
namely: skin, blood, liver, genital organs and the richest of all is the gut. Each
of which has its own microbiome, i.e. collection of microorganisms that live
and work in association. In 2008, the United States launched a five-years project
to explore the microbiome of the human body, named “Human Microbiome
Project- HMP”. The project offered a catalogue that included a huge diversity
of microorganisms living in association with the human body in different body
parts such as: skin, vagina, nose, oral cavity, gastrointestinal tract, blood and
others. Each of which has its own microbiome.
The gut is considered as the most diverse environment for a microbial
collection. The gut alone is colonized by 10 to 100 trillion (1013-1014) bacteria;
besides, other microorganisms like viruses (5.8%), archaea (0.8%) and
eukaryotic microbes (0.5%) (Arumugam et al., 2011; Aziz, 2009). This number
is approximately tenfolds the number of our own cells. It is thought that this
microbiota encodes a surplus of 100-folds unique genes than we do; they have
an immense impact on our physiology, nutrition, general health and body shape
(Qin et al., 2010).
Metagenomics studies provide information about the abundance of
bacterial species and the associated functions, which could indicate for their
survival strategies in the human gut (Arumugam et al., 2011). It has been
roughly calculated that 20%-60% of the human microbiome could not be
cultivated (uncultivable) which in turn resulted in underestimation of their
diversity and influence on the human development. The availability of such data
offers novel approaches for both diagnosis and treatment of many diseases.

This chapter offers a review for human gut microbiome in
different states of health and disease, the microbiome alterations as
well as the effect of chemotherapy and radiotherapy prescription on
the gut microbiota.

1. Microbial Composition of a Healthy Gut

The human gut is colonized by trillions of microorganisms that contribute
to food digestion as well as shaping the state of the body being healthy or
diseased. Unlike the human genome, that shares more than 90% similarity
among different people, the human microbiome is highly variable among people
in state of health. The state of health has been defined as “a dynamic state of
wellbeing characterized by physical, mental, and social potential, which
satisfies the demands of a life commensurate with age, culture, and personal
responsibility” (Bircher, 2005). Healthy adults share a common core
microbiome, a term that was addressed by Qin and colleagues, that shows to be
constant among various people. They reported that 57 different bacterial species
were shared among more than 90% of the people (Qin et al., 2010). The species
constituting the core microbiota are highly abundant in fecal samples being
necessary for performing defined functions within the body (Shade &
Handelsman, 2012). The actual composition of the core microbiota depends on
the inclusion and exclusion criteria that one is defining for a certain group
(Bäckhed et al., 2012). The set of species in the core microbiome may vary
among different geographical locations or ethnic groups (Yatsunenko et al.,
2012). Some studies defined the human core microbiome itself as variable,
being highly affected by external factors as: life style, diet and environmental
factors (Figure 1) (Chase et al., 2015).
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Figure 1: The Concept of Variable and Core Microbiome
Some bacterial species are found to be shared among different people, defining a set of core microbiome.
The core microbiome could vary, being affected by different factors and remain normal (blue arrows)
while other factors may alter the microbiome resulting in a diseased profile (red arrows) (Chase et al.,
2015).
Permission for figure reuse in Appendix 2

2. Distribution of Microbial Species Along the
Gastrointestinal Tract

The gastrointestinal tract is colonized mostly by two main phyla namely
Bacteroidetes and Firmicutes (Huttenhower et al., 2012). The distribution and
colonization of assorted microbial species varies along the GI tract from the
3

small intestine, caecum and large intestine (colon). Although, these parts are
connected without barriers, each of which has its own characteristics such as
the pH, set of active enzymes, level of oxygen and consequently the microbial
composition.
The small intestine, which is characterized by an acidic pH and elevated
oxygen levels, it is colonized by rapidly growing facultative anaerobes. The
presence of bile acid at the proximal end of the small intestine limits its
microbial diversity, since it acts as a bactericide to some species (O’Hara &
Shanahan, 2006). However, limited number of species can withstand this
extreme environment and still be able to survive (103–108 cells/g feces)
(Eckburg et al., 2005). Two families were found colonizing the small intestine
despite its harsh environment, those families are Enterobacteriaceae and
Lactobacillaceae (Gu et al., 2013). Both families are almost saturated at the
distal ends of the small intestines unlike the proximal ends where they inhabit
in low amounts due to the extreme conditions mentioned earlier (Donaldson et
al., 2015).
Unlike the small intestine with its acidic pH, the large intestine is colonized
by much larger cellular densities reaching (1011 cells/g feces) (Eckburg et al.,
2005). It is considered as the most inhabited, being colonized by the most
diverse communities in the human body. The change in pH range from acidic
(1.5-5) to alkaline (5-9) makes it more favorable for different bacteria to
survive. It is worth mentioning that the oxygen content is also increasing in the
large intestine compared to the small intestine, which enhances the probabilities
of bacterial development. The large intestine is usually enriched in
Bacteroidetes (Bacteroidaceae, Prevotellaceae, Rikenellaceae), Clostridiaceae,
Firmicutes (Lachnospiraceae,

Ruminococcaceae), Verrucomicrobia and

Akkermansia muciniphila (Belzer & de Vos, 2012; Scheithauer, et al., 2016).
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3. Functions Attributed to a Healthy Gut Microbiome

The gut microbiota is linked to many aspects in the human body, including
digestion, body weight regulation, maintaining the homeostasis, modulation of
brain development and shaping the host immune response. The microorganisms
colonizing the gut in its state of health can extract nutrients from food that
cannot be digested by human enzymes, as in case of dietary fibers. The dietary
fibers are obtained from the daily intake of fruits and vegetables. They are
digested mainly through fermentation and saccharification performed by the gut
bacteria (Flint et al., 2012). As for the proteins, it was found that members of
the gut Bacteroidetes phylum are responsible for their digestion, while the
bacterium Prevotella ruminicola, of the same phylum, take care of the
carbohydrates in diet (Wu et al., 2011). The carbohydrate degrading bacteria
have carbohydrate active enzymes (CAZymes) encoding-genes in their genome.
The CAZymes can degrade the plants polysaccharides such as pectin, xylan and
cellulose (Flint et al., 2012) that cannot be digested or exhibited limited
digestion by the human enzymes.
The monoamine serotonin 5-hydroxytryptamine (5-HT) is an important
neurotransmitter in GI tract and central nervous system. It is a major regulatory
factor activating numerous receptors in the GI tract along with other organs in
the body. It modulates some feelings including mood and appetite. The
Enterochromaffin cells in the human gut are considered the main source of the
5-HT, since 90% is synthesized in there (Baganz & Blakely, 2013; ChabbiAchengli et al., 2012). The gut microbiome signals the Enterochromaffin cells
to produce the 5-HT (Yano et al., 2015). It is still unclear which member of the
gut microbiota contributes to the denovo synthesis of the 5-HT in gut.
Accordingly, the host-microbial interaction between the residing microbiota
and the human cells plays a major role in the regulation and the balance of the
GI tract.
The intestinal bacteria shape the immune response of the host (Round &
Mazmanian, 2009) by various mechanisms including inhibition of the growth
5

of pathogenic species by secreting bacteriocins (toxic peptides produced by the
bacteria to inhibit the growth of other strains) (Hammami et al., 2013).
Commensal bacterial populations can work in cooperation with the host Paneth
cells of the host, triggering the expression of several antimicrobial factors. Thus,
protecting the intestinal barrier from being penetrated or invaded by other
pathogenic bacteria (Vaishnava et al., 2008).
In the developed countries and west Europe, it was noticed the extreme
hygiene gave rise to several autoimmune diseases, inflammatory bowel disease,
depression (Luna & Foster, 2015) as well as allergies (Azad et al., 2013; Blaser,
2006). Accordingly, a balanced gut microbiome plays a crucial role in
maintaining the homeostasis.

4. Shaping the Profile of the Gut Microbiome

Different factors dictate the nature of the gut microbiome in each
person. Several studies were conducted to determine the effect of
genetic factors on the shape of the microbiota, in identical and nonidentical twins as well as several family members. It was found that
members of one family have highly similar microbiota, in comparison
with unrelated people (Goodrich et al., 2014; Yatsunenko et al., 2012).
Also identical twins share more similar microbiota compared to nonidentical pairs (Hansen et al., 2011; Turnbaugh et al., 2009). This can
only be partially associated with the common diet and life style they
are sharing. However, similar microbial pattern was also identified
among related individuals, thus increasing the possibility of genetic
inheritance effect on the nature of the microbiota. It is still unknown
which alleles in the human genome have a direct effect on shaping the
gut microbiota (Goodrich et al., 2014).
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Other

factors

shaping

the

microbiota

include

environmental

differences and geographic locations that enforce a certain lifestyle or
a certain diet. The diet itself being either the kind of food or the time
of eating, in other words the circadian rhythm induced time of eating
(Hall et al., 2017). An interesting study was conducted on the gut
microbiota of the Japanese, who are famous for their sushi and diet
containing seaweeds. Members of genus Porphyra are considered as
the most important nutritional seaweed found in sushi and other
traditional food. The porphyranase enzyme, originally found in marine
Bacteroidetes,
polysaccharide;
Porphyra

Zobellia

galactanivorans,

porphyran

genus.

What

that

is

grasped

can

found
attention

act

in

on

the

was

the

sulfated

seaweeds
a

gene

from
transfer

phenomenon: the genes encoding for porphyranases were transferred
to the gut bacterium Bacteroides plebeius isolated from Japanese
individuals. Comparative gut metagenome analyses showed that genes
encoding for porphyranases enzymes are frequent in the Japanese
population and absent from the American individuals (Hehemann et
al., 2010). Another study was conducted to compare the microbial
profile of two populations of children (from 1 to 6 years old): one is
from a rural African country: Burkina Faso (BF) and the other from
Italy. Children in BF consume fibers in larger amounts compared to
those from Italy. It was found that the high fiber intake was associated
with increased Bacteroidetes and almost depleted Firmicutes. Fiberbased diet was also coupled with the presence of Prevotella and
Xylanibacter

genera.

Members

of

those

genera

contain

bacterial

species having genes responsible for encoding the enzymes required
for cellulose and xylan

degradation, that

were absent

in

Italian

children (De Filippo et al., 2010). The two abovementioned studies
showed a clear correlation between the geographic location, regular
diet, life style and the gut microbiome.
Age also plays a major role in shaping the microbiota at various
stages of life (Figure 2). The relationship between the gut microbiota
and age starts at birth and depends on the mode of child delivery.
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Cesarean section delivery affects the microbiota profile in comparison
with

the

vaginal

Actinobacteria

delivery.

and

In

case

Bacteroidetes

phyla

of

cesarean
were

section,

decreased;

the
while

Firmicutes phylum had higher richness and evenness. The cesarean
section-delivered infants also a less abundance microbiota till they
reached the age of one month (Rutayisire et al., 2016). On the other
hand,

vaginally

delivered

infants

had

higher

colonization

of

Bacteroides genus (Ebihara et al., 2013; Grönlund et al., 1999). It is
important to mention that several studies found that there is no
differences in Lactobacillus genus abundance from day zero till the
age of one month in both modes of delivery (Ebihara et al., 2013;
Grönlund et al., 1999; Huurre et al., 2008).
After acquiring a primary gut microbiome profile, neonates start to
develop their own microbiome till reaching the age of three years
(Kundu et al., 2017). The shift to adult microbial profile occurs in
parallel with the weaning process and the introduction of solid-food to
the diet (Bergström et al., 2014). The microbial development at this
stage relies on the food introduced and any medical treatment or
antibiotics administrated during this period of development. Therefore,
it is recomended to minimize the chemical intervention during the
aforementioned developmental period (Koenig et al., 2011). A stable
microbiome begins by the age of 3 years, consisting of six phyla, two
of which are abundant (Bacteroidetes and Firmicutes) (Figure 3),
while

the

Actinobacteria),

other
and

phyla
even

are
less

less

abundant

Fusobacteria,

(Eckburg et al., 2005).
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and

(Proteobacteria,
Verrucomicrobia

Figure 2: Gut Microbiota Profile Development with Age
The gut microbiota profile development from time of birth till reaching the adults’ profile. During
prenatal development, some theories support the prenatal is sterile and acquire the first microbiome
from the mother during delivery; other theories support that prenatal start to acquire their microbiome
in the womb. The neonates’ microbiome depends on the mode of delivery and start to develop when
the child food intake is changed. During early stage of development and puberty; the microbial diversity
increase, the core microbiome becomes established, while the variable microbiome is shaped according
to one’s lifestyle and environment. The microbial development occurs in parallel with the organs
development, elongation of the intestines, allowing more niches for the microbiome to develop, increase
in number and increase in diversity. The adulthood microbiome is considered the most stable; although,
changes are still acceptable according to state of health and disease and other factors as aforementioned
(Kundu et al., 2017).
Permission for reuse in Appendix 2
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Figure 3: Variation in Microbiota Composition with Age
Actinobacteria (yellow), Bacteroidetes (red), Firmicutes (blue), Proteobacteria (pink). The numbers
represent the age groups (from neonates to centenarians). The Firmicutes dominate the adult gut
microbiome compared to the neonates’ microbiome that is dominated by Actinobacteria. By increasing
age groups (above 70 years old), the Bacteroidetes and Proteobacteria increase while the Actinobacteria
decreases noticeably (Odamaki et al., 2016).
Authors’ permission for reuse in Appendix 2.

5. Dysbiosis of gut microbiota

Dysbiosis is defined as a state of imbalance or shift from the
normal microbiota profile. Gut microbiota dysbiosis has been linked to
several diseases as inflammatory bowel disease (IBD), autism, stress,
depression, immunity related diseases and several others. Many links
were created to the gut microbiota, being either affected by the disease
or the imbalance being the cause of the disease. The state of imbalance
could occur as a result of several factors including: exposure to drugs,
diet alterations, toxins and radiation. The imbalance could be either a
change in the proportionality of the already existing bacteria (as in
case of increased Lactobacillus in obese individuals) (Armougom, et
10

al., 2009) or could appear because of the introduction of undesired
bacteria as Clostridium difficile (C. difficile) that may develop several
complications.

5.1. Changing the Proportionality among the Symbiotic
Bacteria

Symbiotic bacteria reside in the host in a well-balanced form
that should be maintained to ensure a healthy state of life (Round &
Mazmanian, 2009). Whenever the balance is interrupted, a shift from
health state to disease occurs (Chow et al., 2010).
Obesity

is

a

common

disease

linked

with

abnormal

proportionality in the gut microbiota profile. Obese or overweight
individuals

usually

consume

excessive

amounts

of

fats

and

carbohydrates in their diets; moreover, their lifestyle does not enforce
much physical exercise. Accordingly, calories are stored in the body in
the form of fats in adipocytes (Chakraborti, 2015). Since the gut
microbiota plays a vital role in the food digestion and production of
metabolic
production

end-products,
of

certain

some

phyla

metabolic

are

directly

end-products

linked

that

to

the

govern

the

absorption of the digested food in the host body. Members of phylum
Firmicutes are

correlated

with

the

production

of

butyrate,

while

acetate and propionate are usually correlated with Bacteroidetes and
Actinobacteria

(Chakraborti,

2015).

Accordingly,

the

abundance

of

each phylum depends upon the availability of the target substrate in
diet (Shoaie et al., 2013). In obese individuals, some studies reported
an increase in Firmicutes over the Bacteroidetes (Abdallah Ismail et
al., 2011; Bervoets et al., 2013; Hartstra et al., 2015). Members of
phylum Firmicutes are more concerned with degradation of high
energy food, thus raising the amount of lipid droplets leading to higher
weight gain (den Besten et al., 2013; Semova et al., 2012). On the
11

other

hand,

was

no

observed

difference

in

the

proportion

of

Bacteroidetes at the phylum level between obese, non-obese and obese
undergoing weight loss diet. Yet proportion of the Firmicutes was
reduced in the group of obese undergoing weight loss diet (Duncan et
al., 2008).

5.2. Invasion by Pathogenic Bacteria

Symbiotic bacterial strains are considered as a defense line,
protecting the host from invading pathogens. Those symbiotic bacteria
are perfectly occupying the available niches in the gut. Therefore, the
invading pathogenic bacteria have to compete for space and food
resources with the already existing and well-adapted symbiotic strains
and escape the host immune response (Rohmer et al., 2011). Despite
the high protection level in the gut, some pathogens succeed in the
invasion and colonization of the gut niches.
Clostridium difficile is one of the gut pathogens that can escape
the defense line and colonize in the intestine. Infection by C. difficile
is symptomatic, appearing in the form of diarrhea that can even
become more complicated resulting in pseudomembranous colitis and
toxic megacolon, and might even lead to the death of the patient
(Gerding,

2004).

C.

bacterium

(McDonald

difficile

is

et

2006;

al.,

a

gram
Rupnik

positive,
et

al.,

spore-forming
2009).

The

persistence of spores renders C. difficile as a major health issue, since
the infection is usually associated with prolonged hospital-stays along
with antibiotics prescription (Buffie et al., 2012). Long exposure to
antibiotic treatment can alter the natural microbiota, decreasing its
richness and diversity for a period of time (antibiotic perturbation)
following the treatment, after which the host can retain the original
microbiota profile. Clindamycin and cephalosporins are among the
antibiotics associated with the possible development of C. difficile
12

infection. The C.

difficile makes a great use of the dysbiosis occurring

post antibiotic treatment, its spores in the surrounding environment
can initiate the invasion (Lawley et al., 2010). In an experiment
performed on mice, consumption of clindamycin antibiotic led to
expected gut microbiota perturbation. In the absence of C. difficile
spores, the mice were able to re-structure their original microbiota
profile within 21 days after antibiotic treatment. On the other hand, in
the same experimental set up, but in presence of C. difficile spores, the
bacteria succeeded in the invasion. Moreover, the gut microbiota
dysbiosis became persistent till 49 days post-clindamycin treatment
(Lawley et al., 2012).

5.3. Differentiation Between Commensals and Pathogens

The gut can differentiate between symbiotic bacteria or beneficial
commensals
recognized

from
by

intruding

ones

pathogens.

immune

system

Symbiotic
once

bacteria

acquired

in

are
early

developmental stage (Hooper et al., 2012). During the weaning period,
the host Paneth cells secrete anti-microbial peptide that targets grampositive pathogens while gram-negative commensals are not affected
(Hooper et al., 2003). The host uses pattern recognition receptors, such
as

Toll-like

receptors

(TLRs),

to

identify

different

bacterial

components (Ferreira et al., 2014). When TLRs recognize a symbiotic
bacterial factor, homeostasis is induced. On the other hand, when
pathogenic bacteria are recognized by the TLRs, inflammation is
induced along with secretion of antimicrobial peptides to eradicate the
pathogens (Figure 4) (Burdelya et al., 2008; Hsiao et al., 2008).
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Figure 4: Host differentiation mechanisms between symbiotic and pathogenic bacteria
(4A): Identification of symbiotic bacteria in Orthobiosis (balanced beneficial symbionts in microbiota)
(4B): Dysbiosis accompanied with pathogenic bacteria identification by TLR (Ferreira et al., 2014).
Permission for figure Reuse in Appendix 2

5.4. Dysbiosis Treatment

When a gut microbiota profile is identified as unhealthy or
unfavorably altered, a treatment could be offered to shift it to a healthy
profile.

Such

treatment

relies

on

getting

rid

of

pathogens

or

introducing missing taxa. One simple method for a desired microbial
shift is following a healthy diet. The microbiota can undergo a rapid
shift based on diet habits (David et al., 2014). Other ways for desired
microbial

shift

will

be

addressed

below,

which

includes

the

administration of probiotics, prebiotics, tailored drugs as Ecobiotics
and fecal microbiota transplantation (FMT) from healthy donors.
Probiotics are defined by the World Health Organization as
“live microorganisms that can provide benefits to human health when
administered in adequate amounts, which confer a beneficial health
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effect on the host” (WHO, 2001). The most common bacterial genera
in probiotics are Bifidobacteria and Lactobacilli. Probiotics’ beneficial
effects have been linked to alleviation of traveler’s diarrhea, antibiotic
associated diarrhea and inflammatory bowel disease (Kaur et al.,
2009). The probiotics mode of action is species specific. Some
L.bacilli

can

produce

defensins

(antimicrobial

peptides)

that

are

normally produced by the host intestinal cells (Möndel et al., 2009).
Saccharomyces boulardii can lessen ulcerative colitis by competing
with

Citrobacter

rodentium

which

are

pathogenic

bacteria,

for

adherence to the host epithelial cells (Wu et al., 2008). Probiotics
could be obtained either from food sources as yogurt and milk or
administrated as drugs. The amounts of probiotics administrated are
determined as colony forming unit (CFU). It is important to mention
that the effect of probiotics is transient and diminishes in about 4
weeks after stopping probiotics intake (Gogineni et al., 2013).
Prebiotics

are:

“A

non-digestible

food

ingredient

that

beneficially affect the host by selectively stimulating the growth and/or
activity of one or a limited number of bacteria in the colon thus
improves the host health” (Gibson & Roberfroid, 1995). They are
found in some food sources including garlic, onion, wheat, soybean
and asparagus (Van Loo et al., 1995). Prebiotics are mainly composed
of carbohydrates although they might include some non-carbohydrate
moieties. One major criterion to identify a food source as a potential
prebiotic is its ability to resist hydrolysis by gastric enzymes, transfer
to the intestine and undergo fermentation in the large intestine, thus
enabling the intestinal microbiota to flourish
of

the

microbiota residing

in

the

(Xiao et al., 2014). Most

large intestine

are

anaerobes;

therefore, their energy uptake is based on fermentation. This reflects
the indirect effect of prebiotics and its importance in enhancing the
activity and growth of the intestinal microbiota.
Many

pharmaceutical

companies

formulate

drugs

to

supplement patients with useful microorganisms in a form of capsule
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to shift the diseased profile to a healthy state, thus preventing or
treating

the

microbiome-linked

could be probiotics,

diseases.

synbiotics or

The

formulated

Ecobiotics.

capsules

The synbiotics are

formulations based on prebiotics and probiotics together. The choice
of each should be in synergism, that is the prebiotics favoring the
growth of the probiotics chosen. One example for a synbiotic drug
could be Bifidobacteria and oligofructose, while the same prebiotic
oligofructose
Lactobacilli

cannot
for

a

be

grouped

synbiotic

with

the

formulation

requires Inulin as a substrate)

probiotic

(since

the

bacteria

Lactobacilli

(Schrezenmeir & de Vrese, 2001). The

new trend of ecobiotic drugs is rapidly growing. Ecobiotics are based
on

the

selection

of

desired

bacteria

from

healthy

stool

and

concentrating their spores in the form of capsule to shift certain
diseased profiles to healthy ones (Hoffmann et al., 2017).
Several microbiome centers are being established worldwide,
and

many

pharmaceutical

companies

started

to

benefit

from

the

available data to develop various medications. SERES Therapeutics in
the United Kingdom is working on several ecobiotic drugs, in clinical
trials, that shift the microbiota from diseased states as recurrent of C.
difficile

(SER-109),

primary

colitis

(SER-287)

ulcerative

C.

difficile
to

a

infection
health

(SER-262)

state.

and

MicroBiome

Therapeutics in the United States released its first product: NM504, in
early 2017, targeting the GI dysbiosis in diabetic patients. Novartis has
also teamed up with the University of California in San Francisco and
funded $8.1 million to support microbiome research. Accordingly, this
field of science became one of the basic research requirements for
pharmaceutical developments and drug discovery.
Fecal

Microbiota

transplantation

(FMT)

is

another

possible

solution for shifting the diseased microbiota profile to a healthy one or
a healthier microbiota. FMT was first reported in late the 1950s in
Colorado. Enemas aimed at treating patients with pseudomembranous
colitis as a result of C. difficile infection (Borody & Khoruts, 2012;
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Eiseman et al., 1958). Gustaffson and colleagues studied microbiotaassociated

characteristics

(as interaction

with

antibiotics,

symptoms

ranging from diarrhea to membranous colitis) in 32 patients before and
after FMT; the effect of FMT on the microbial shift was reported four
days post transplantation (Gustafsson et al., 1999). It is important to
mention that in case of C. difficile infection; the patients’ microbiota is
almost destroyed by the intensive use of antibiotics. Accordingly,
implementation

of

a

new

healthy

microbial

profile

is

applicable

(Borody & Khoruts, 2012). As for other diseases linked to microbiota
disruption or imbalance as obesity, IBD or chronic fatigue, more
studies are testing the effect of FMT on the recipient’s health. In a
study testing the effect of FMT between lean and obese men, the obese
recipients had a noticeable decrease in fasting triglycerides level
compared to self-recipients (placebo group) (Vrieze et al., 2012).

6. Relationship Between Gut Microbiota and Cancer

The

relationship

between

the

gut

microbiota

and

Cancer

development at various sites of the body is complicated, entering the
dilemma of which came first (Figure 5). Is the gut microbiota
dysbiosis the cause of cancer development? Or is it cancer and its
associated cancer treatment protocols that caused dysbiosis? How will
the response to treatment be in a cancer patient with an altered gut
microbiota?
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Figure 5: Relationship between dysbiosis, cancer and cancer treatment
A complicated relationship between dysbiosis, cancer and cancer treatment protocols. Gut microbiota
dysbiosis might give rise to cancer and vice versa. While the common cancer treatment plans can result
in gut microbiota dysbiosis.

6.1. Is the Gut Microbiota Dysbiosis Considered a Cause
for Cancer Development?

Gut microbiota dysbiosis was linked to several cancer types
including colorectal cancer (CRC), hepatocellular carcinoma (HCC)
and gastric cancer. An observational study linked CRC and lymph
node metastasis with the increased colonization by the pathogenic
bacterium,

Fusobacterium

nucleatum

(Castellarin

et

al.,

2012).

Cuevas-Ramos and colleagues have linked the development of CRC to
the colonization of Escherichia coli of group B2 in mice (CuevasRamos et al., 2010). The genomic DNA of 40%-60% of group B2 E.
coli bacteria contains a pathogenicity island (54-kb) known as pks
(McCarthy et al., 2015), the genes in pks island encode for the
synthesis of a polyketide-peptide genotoxin named colibactin. The
colibactin peptide has the ability to induce DNA double strand breaks
in the host colon enterocytes (Nougayrede et al., 2006). The effect of
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colibactin on DNA damage was assessed in mice and was comparable
to the damage induced by 0.5 Gy of gamma radiation. Both colibactin
and 0.5 Gy of whole body irradiation were able to induce DNA
mutations,

aneuploidy,

chromosomal

instability

and

consequently

colon carcinogenesis (Cuevas-Ramos et al., 2010).
Gut
explained

microbiota
earlier.

dysbiosis

Another

link

has

been

linked

was

established

to

obesity

between

the

as
gut

microbiota dysbiosis, obesity and HCC. Yoshimoto and colleagues
have described the complex link between high-fat diet, microbiota
dysbiosis and HCC development in mice models (Yoshimoto et al.,
2013). The high-fat diet can directly shift the microbiota profile, that
in turns affect the microbial by-products produced, one of which is the
deoxycholic acid (DCA). The DCA results from microbial bile-acid
metabolism and adversely leading to DNA damage. Elevated DCA
level

induces

the

production

of

senescence-associated

secretory

phenotype (SASP) that is a group of proteases, chemokines and
inflammatory

cytokines.

tumorigenesis.

Liver

bacteria

and

The

diseases

bacterial

elevation
are

of

associated

components

SASP
with

within

the

enhances

the

translocation

of

patients’

body

(Roderburg & Luedde, 2014). Another study highlighted the presence
of the stomach pathogen H. pylori in the liver of patients with HCC (8
positive H. pylori out of 20 HCC) (Huang et al., 2004).

6.2. A Reciprocal Link Between Cancer Treatment
Medications and Gut Microbiota

Common treatment protocols administrated to cancer patients
are usually relying on chemotherapy, immunotherapy, radiotherapy or
a combined treatment protocol. Each of which can cause a shift in the
patients’ gut microbiota. Moreover, treatment protocols are sometimes
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combined with antibiotic administration, which adds a burden on the
gut microbiota.
Zwielehner and colleagues studied the effect of 17 different
chemotherapeutic

agents

in

presence

and

absence

of

antibiotic

administration and radiation (Zwielehner et al., 2011). Their study
relied

on

PCR

fingerprinting

on

denaturing

gradient

gel

electrophoresis (PCR-DGGE), quantitative real-time PCR along with
454-sequencing for samples from only two patients. Accordingly, the
results reflected overall species abundance with special emphasis on
the potential pathogenic bacteria: Clostridium cluster IV. The study
reported a steep drop in bacterial species richness, in comparison with
healthy controls, after the first shot of chemotherapy. It also described
a “rebound-effect” in the bacterial richness of the gut microbiota in
their last time point (5-9 days after chemotherapy), but with a different
composition.

Another

study

focused

on

the

effect

of

Cyclophosphamide (CTX) on the gut microbiota in mice models
(Viaud et al., 2013). CTX did not alter the intestinal microbiota
instantaneously (24 and 48 h after the first shot). However, the
dysbiosis in the small intestine was only reported one week after the
drug administration. Aside from the dysbiosis of gut microbiota, an
important link was made between the absence of gut microbiota and
resistance to CTX. It was found that the tumors in germ free mice
were resistant to CTX treatment.
The

link

between

the

immunotherapies

targeting

the

programmed cell death protein-1 (PD-1) and the gut microbiome was
studied in Melanoma cancer patients (Gopalakrishnan et al., 2018) and
patients suffering from epithelial tumors (Routy et al., 2018). The two
studies have described a “favorable profile” of the gut microbiome
was described in cancer patients, who responded to anti-PD1 drugs.
Gopalakrishnan and colleagues described the favorable profile of the
responders patients with higher alpha diversity and increased relative
abundance of family Ruminococcaceae along with Faecalibacterium,
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compared to the non-responders gut profiles (unfavorable) that has
increased abundance of Bacteroidales and

decreased alpha diversity

(Gopalakrishnan et al., 2018). A favorable gut microbiome was also
linked to a better antigen presentation and presence of higher level of
effector T-cells in the tumor micro-environment. Routy and colleagues
linked

resistance

to

immunotherapies

as

immune

check

point

inhibitors (ICI) with altered gut microbiome (the unfavorable profile
described

by

(Gopalakrishnan

et

al.,

2018)).

They

also

found

Akkermansia muciniphila to be common among responders to ICI.
Accordingly, they concluded the possibility of manipulating the gut
microbiome to decrease the resistance to ICI through FMT along with
providing Akkermansia muciniphila bacterium in the form of oral
supplementation (Routy et al., 2018).
The term pharmacomicrobiomics started to appear with the
HMP. It was defined as “The effect of microbiome variations on drug
disposition,

action,

and

toxicity” (Rizkallah

et

al.,

2010).

The

interdisciplinary field of pharmacomicrobiomics adds a great value to
microbiome research, since determining the interaction between the
gut microbes, in either health or disease, and various medications can
offer a better response of the same drug by manipulating the patients’
gut microbiome.
The
metabolism,
ecological

TIMER
E:

(T:

Translocation,

enzymatic

variation)

degradation,

relationship

between

I:

Immunomodulation,

M:

R:

reduced

and

diversity

the patients’

microbiome

and chemotherapeutic drugs offered a better view for the complicated
nature of this relationship (Alexander et al., 2017). The TIMER is a
collective description for the modulation of the gut microbiota to
different chemotherapeutic agents. Each of the TIMER component
represents a different mechanism by which the gut microbiota can
facilitate the antitumor

effect

of

various chemotherapeutic agents.

CTX chemotherapeutic drug induces the translocation of some grampositive bacteria to reside in the lymphoid organs. The translocated
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bacteria induce the production of pathogen T-helper 17 that in turn
enhances the tumor response to the antitumor activity of CTX (Viaud
et al., 2013). Iida and colleagues highlighted the importance of having
intact commensal microbes in the tumor microenvironment that is
required for a proper immunomodulation of myeloid-derived cells
activated

by

immunotherapy

and

chemotherapy:

CpG

oligodeoxynucleotides and Oxaliplatin respectively (Iida et al., 2013),
beacause the germ-free mice responded poorly to the aforementioned
drugs.
Accordingly, it became necessary to understand the role of the
commensal bacteria in antitumor effect of various chemotherapeutic
agents, to enable the compensation for the commensal deterioration
towards a better response to the therapy.

6.3. Link
Between
Radiotherapy
Microbiota: Is It Only Dysbiosis?

Radiotherapy

is

administrated

as

a

and

palliative

Gut

or

curative

therapy to up to 50% of the cancer patients, either independently or in
combination with chemotherapy (Abbasakoor et al., 2006). Focusing
on the radiotherapy directed to the abdominal and pelvic regions,
radiation enteropathy is the main concern in determining the coming
therapeutic plan. Several symptoms arise after the first or second week
of treatment as a side effect of
including:

bloating,

diarrhea,

radiation in abdominal

imperfect

food

absorption,

region

abdominal

pain and nausea (Bismar & Sinicrope, 2002). The side effects are
usually the driving force for the dose limitation or discontinuation,
thus affecting the patients’ health. Radiation associated enteropathy is
usually resulting from the effect of radiation on the intestinal region.
Although the small intestine is not a common target for radiation, but
its large surface area and the high sensitivity of its mucosal lining to
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radiation

are

the

main

reason

for

the

enteropathy

side

effects

appearing on the patients (Packey & Ciorba, 2010).
An important study conducted on mice, has tested the role of
the

gut

microbiota

in

determining

the

sensitivity

to

radiation

(Crawford & Gordon, 2005). The mice in this study were subjected to
a lethal dose (16 Gy) of total body irradiation (TBI) followed by bone
marrow transplantation (BMT). All germ-free mice survived (more
than 40 days) compared to the conventionally raised mice, where 52%
died in 7 days post TBI. To further confirm the relation to the gut
microbiota; the germ-free mice were inoculated with fecal samples
from the conventional mice then subjected to the same dose (16 Gy) of
TBI followed by BMT, 44% died in 7 days. A more recent study that
was

conducted

on

(Gerassy-Vainberg

et

mice
al.,

by
2018)

Gerassy-Vainberg

and

colleagues

has

the

relationship

focused

on

between post-radiation injuries, gut microbiota dysbiosis and the effect
of dysbosis on increasing the liability to inflammations. Accordingly,
a sequential effect of radiation was proposed as follows: radiation
inducing gut microbiota dysbiosis, the altered microbiota induces a
higher secretion of Interleukin-1b which consequently increases the
susceptibility to tissue damage and appearance of proctitis.
The impact of radiation on gut microbiota was assessed in a
group of gynecological cancer patients (45-64 years old) (Nam et al.,
2013).

The

composition

study

reported

after

receiving

a

massive
radiotherapy.

change

in

Firmicutes

microbiota
phylum

decreased by 10% while the Fusobacterium decreased by 3%. The
post-radiotherapy samples collected in the follow-up period (one to
three months after radiotherapy) showed a remold or reshaping of the
gut microbiota.
In a nutshell, the relationship between gut microbiome, cancer
development, chemotherapies,

immunotherapies and
23

radiotherapy

are

ultimately complicated. The microbial balance during chemotherapy
and immunotherapy may lead to a better response to treatment. While
the presence of gut bacteria during radiotherapy has several unwanted
side effects. On the other hand, the total absence (as in germ free
mice) can render the patient resistant to lethal doses of radiation.
Accordingly, the proper manipulation of gut bacteria during cancer
treatment can increase the success rates of the prescribed treatment
protocols. Therefore, this study has focused on understanding the link
between infants’ gut microbiota and radiotherapy treatment.

Chapter 2: Study Objective and Design
1. Study Objective

This study is an observational study, to determine the effect of
radiotherapy on the infants’ gut microbiome.

2. Study design
In the current study we analyzed 10 fecal samples, obtained from two
healthy individuals and three cancer patients. It included two sets of controls:
self-control (same patient before starting radiotherapy sessions) and healthy
individuals. The healthy is defined as not consuming any chemotherapeutic
agents or antibiotics (antibiotic free period was defined by at least 1 month
before sample collection) and never exposed to radiotherapy before. All the
participants in the study (patients and healthy individuals) are males, within the
age range 3.5-7 years old.
Patients in the current study suffer from Rhabdomyosarcomas in the
pelvic region. Such type of cancer receives a high dose of radiation. The patient
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receives 50.4 Gy (180 cGy/fraction). The sample collection points were defined
as follows: day 0: before starting radiotherapy sessions, mid-point: ranging from
day 12 to day 16 and the last collection point: day 26-28. Patients with
Rhabdomyosarcomas follow a combined treatment protocol including
chemotherapy (Cyclophosphamide, Vincristine and Dactinomycin) and
radiotherapy; 28 fractions of 50.4 Gy (180 cGy/fraction). The patients started
the radiotherapy sessions either after 12 weeks of chemotherapy (Patient 1 and
patient 3) or after 4 weeks of chemotherapy (patient 2). During the
chemotherapy; a set of antibiotics (Table 1) is usually prescribed according to
the patients’ case or needs.
Table 1: Set of Antibiotics prescribed before and during radiotherapy

Antibiotic

Antimicrobial

Patient

Patient

Patient

Spectrum

(1)

(2)

(3)

Before Radiotherapy
Amikacin

Gram-negative

NA

Azithromycin

2 months NA

NA

Ceftriaxone

Enteric bacteria
and other
eubacteria and
several
pathogenic
bacteria
Broad spectrum

3 months NA

Less than
1 months

Ciprobay

Broad spectrum

NA

Less than
1 months

Meropenem

Broad spectrum

Rocephin

Broad spectrum

Less than
2 months

NA

Less
than 1
month
NA

NA

NA

Less than
1 months

(Ciprofloxacin)
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NA

Less than
1 months

Sulfamethoxazole and
trimethoprim
Sutrim

Tavanic
Zithromax

Broad spectrum
and several
pathogenic
bacteria
Broad spectrum
and several
pathogenic
bacteria
Broad Spectrum

4 months Less
than 1
month

Less than
1 month

2 months Less
than 1
month

Less than
2 months

Enteric bacteria
and other
eubacteria and
several
pathogenic
bacteria

4 months Less
than 1
month

NA

NA

Less than
2 months
NA

During Radiotherapy
Augmentin

Broad spectrum

NA

Day 2

NA

Ceftriaxone

Broad spectrum

NA

NA

Day 13

Levofloxacin

Broad spectrum

NA

NA

Day 6

Sulfamethoxazole and

Broad spectrum
and several
pathogenic
bacteria
Broad spectrum
and several
pathogenic
bacteria

Yes

Day 2

Day 22

NA

Day 15

NA

trimethoprim
Sutrium

*Days and Months are calculated with respect to the start of radiotherapy sessions.
**Duration of antibiotic course ranges from 4 days to 3 weeks.
***Antibiotic spectrum information is retrieved from DrugBank Database (Wishart et al., 2018).
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Chapter 3: Materials and Methods
1. Sample collection and informed consents

An institutional review board (IRB) approval was granted from the AUC
(Approval of study #2016-2017-041) – Appendix 3. All participants have
signed (child assent form) and the guardians have approved the participation in
study and signed a parental permission form. Fecal samples were collected from
the participants, by the help of their parents, in sterile falcon tubes, transferred
on ice to the lab at Zewail City and stored in -80°C freezer until DNA extraction.

2. DNA extraction

Microbial DNA was extracted from the collected fecal samples by DNA
extraction kit from stool, QIAamp DNA stool mini kit (Qiagen, USA),
according to the manufacturer’s instruction. The protocol used enhances the
nonhuman DNA over the human DNA extracted from the sample, through
optimization of the lysis conditions. The DNA was eluted in 50 µl elution buffer
provided by the kit and stored in -20°C.

3. 16S rRNA sequencing

The extracted DNA was sent to Eurofins Genomics in Germany for
sequencing of 16S rRNA. The sequence was performed on Illumina MiSeq
platform, targeting V3-V5 variable regions of the 16S rRNA. The run was
performed on 2x300 paired-end reads. The target region (V3-V5) length is
approximately 700 bp; accordingly, the obtained reads do not overlap.
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4. Data Analysis

The

16S

rRNA

sequencing

data

received

from

Eurofins

Genomics were already demultiplexed (remove barcodes and assign
each read to its original sample). The analysis was completed on
Qiime2

pipeline

(version

2017.12),

q2cli

command

line

interface

(Qiime2 script in appendix 1). The denoise command was used
followed by length trimming to 230 bp. Feature table was constructed
on the same program (also referred as OTU table) using “Deblur”
approach for OTU table construction, that is compatible with Hi-seq
and Mi-seq Illumina results. The Deblur approach uses an error
profile, operating on per-sample bases and depends on the read length
and

diversity

sensitivity

and

in

amplicon

requires

sequences.

lower

Thus,

computational

it

offers

powers

a

higher

compared

to

other OTU clustering algorithms (Amir et al., 2017).
Taxonomy classes were assigned using the constructed feature
table in comparison with SILVA database (Silva-119 99% OTUs fulllength sequences). Unrooted phylogenetic tree was also constructed on
Qiime2 (qiime phylogeny fasttree). The taxonomic classification was
appended to the feature table and exported as a biom format file, the
phylogentic tree was exported as (Newick tree format) and

the

sequences corresponding to the classified OTUs were exported as fasta
file.

All

exported

files from

Qiime2

analysis were imported

to

phyloseq package (McMurdie & Holmes, 2013) on R-CRAN for
figures plotting. It is important to mention that reads were not rarefied
to an even sampling depth (McMurdie & Holmes, 2014)
Another OTU clustering algorithm was tested through USeacrh
pipeline (Edgar, 2010), that resulted in clustering to 792 OTU.
However,

the

taxonomy

accessible through

assignment

the free

version

Appendix 1).
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on
of

this

platform

USearch

(Script

was
used

not
in

Chapter 4: Results
1. Reads quality and optimization

A total of 10 fecal samples obtained from two healthy controls
and three cancer patients (three samples on three-time points from
each patient, except patient 1). Although, the original experimental
design targeted a larger set of patients, only three could be reached due
to the following constrains: (1) limitation of the number of patients
with Rhabdomyosarcoma since it is a rare cancer type, (2) targeted age
range; the patients were young and were not aware of participating in
a study, (3) most of the patients were suffering from constipation
before starting radiotherapy that made the sample collection at point
zero

(pre

radiation)

a

challenging

Rhabdomyosarcoma

in

the

treatment

of

chemotherapy

and

protocol

Dactinomycin),

pelvic

radiotherapy

task.

region

The

patients

underwent

a

(Cyclophosphamide,

(50.4

Gy

on

28

with

combined
Vincristine

fractions;

180

cGy/fr.) and a complex set of antibiotics as described previously in
table 1. The microbial DNA was extracted and used for 16S rRNA
sequencing

on

Illumina

MiSeq

platform,

targeting

V3-V5

region,

paired-end reads (2x300).
The high throughput sequencing generated a sum of 904,685
reads, containing a yield of 510,237 bp (mean reads per sample =
42,407.9 and median reads per sample = 41,645.5) (Figure 6). The
average read length obtained (Forwards reads ~ 280 bp, Reverse reads
~ 250 bp). All reads were trimmed to 230 bp after denoising on qiime2
(qiime deblur denoise-16S).
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A

B

Figure 6: Validation of sequencing reads
Overview of sequencing reads (A): number of reads obtained
number of reads obtained were from sample (pre_patient_1)
reads were from Mid_Pateint_3 (B) read length and quality
reverse reads from each sample. The average reads length is
while the reverse read length ranges between 200 bp to 250 bp.
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from each sample. The least
while the highest number of
score for both forward and
280 bp for all forward reads

2. Alpha diversity analysis

All

indices

of

alpha

diversity

measures

(Observed

OTU,

Chao1, ACE, Shannon, Simpson, Inverse Simpson and Fisher) all
showed a higher diversity in healthy controls compared to cancer
patients in the three-time points collected (Figure 7). After completing
the radiotherapy treatment along with the antibiotics courses (Last,
blue) the alpha diversity has generally declined when compared to the
mid-point (after 12-15 fractions) and pre (before radiation). The out
layers at each time point are obvious, this could be attributed to the
personal variations between the patients, along with the variation due
to the set of antibiotics prescribed, antibiotic course duration and
antibiotic

course

timing

relative

to

the

radiotherapy

and

sample

collection time.

Figure 7: Alpha diversity analysis across different time points
Box plot showing different alpha diversity indices across the time points (Pre: before
radiation, Mid: after 12-15 fractions and Last: after 26-28 fractions of radiation that is
equivalent to 50.4 Gy) the control are healthy participants (never subjected to chemotherapy
or radiotherapy before and at least one month free of antibiotics before the sample
collection time).
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3. Alpha diversity per sample

Alpha diversity measures (Chao1 and Shannon) per sample did
not

indicate

a

direct

relationship

between

exposure

to

radiation,

consuming intensive antibiotics courses and the relative abundance of
all bacterial species per sample (Figure 8). Surprisingly, patients 1 and
2 experienced an increase in the alpha diversity after the two
aforementioned

exposures.

Unlike

patient

3

who

experienced

a

massive drop in alpha diversity. On the other hand, a pattern or a
relationship was inferred between high alpha diversity and response to
treatment (Table 2). The decreased bacterial abundance was associated
with a positive response to radiotherapy and vice versa. It is important
to mention that the Chao1 index reflect the richness only (number of
bacterial species per sample),

while Shannon index reflects both

richness and evenness (relative abundance of species that make up the
richness).

Figure 8: Chao1 and shannon indices per sample
Chao1 and Shannon indices of alpha diversity per sample. Neither index indicated a direct relationship
between exposure to radiation and alpha diversity
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Table 2:Alpha diversity with reflection to the response to radiation
Sample

Chao1

Shannon

Control-1

111.2

3.184

NA

Control-2

127

3.11

NA

Pre-patient-1

104.25

3.121

Mid-Patient-1

134

3.651

Pre-Patient-2

44

1.82

Mid-Patient-2

74.167

2.19

Last-Patient-2

79.333

2.717

Pre-Patient-3

46

1.894

Mid-Patient-3

10

0.143

Last-patient-3

15

0.12

NA: Not Available
R: Responded to radiotherapy
NR: Not Responding to radiotherapy
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Response to treatment

NR

R

R

4. Describing the variation in the bacterial abundance at
different taxonomic levels

At the phylum level, the two healthy controls showed normal
variation between the four most abundant bacterial phyla (Firmicutes,
Bacteroidetes,
domination

Proteobacteria
of

Firmicutes

and

Actinobacteria)

and

relatively

(Figure

high

9),

with

abundance

of

Proteobacteria (Odamaki et al., 2016). Control-2 showed relative high
abundance

of

Actinobacteria

compared

to

Control-1.

However,

a

related point to consider is that up to date, there is no database for the
Egyptians’ gut microbiota profile to which the controls could be
compared to obtain a correct reflection with the Egyptian diet and life
style.
After the exposure to different doses of radiation that ranged
between (21.6 Gy and 50.4 Gy), along with the antibiotic courses
(Table-1) the relative abundance of Firmicutes decreased while the
Proteobacteria

increased

in

the

three

patients.

This

comes

in

agreement with the previous results of Wang and colleagues (Wang et
al., 2015). The phylum abundance frequency table (Table-3) showed
the expected disturbance of microbial phyla in cancer patients when
compared to the controls. However, when comparing each patient to
himself (at the different time points collected), it was found that
Actinobacteria, Bacteroidetes and Proteobacteria phyla increased after
antibiotics and radiation while Firmicutes decreased. This can give a
better insight for the increase in alpha diversity visualized earlier
(Figure 8).
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A

B

Figure 9: Relative abundance of bacterial species at the phylum level
The abundance of the four major bacterial phyla across different samples. (A) Bar plot showing the
relative abundance of the four major phyla in controls and patients. (B) Heat map showing the abundance
at the phylum level. The heat map showed that Firmicutes is the dominant phylum across all samples, in
exception of patient 3, who has the Proteobacteria phylum dominating over all others. The two healthy
controls and patient 1 (in both time points) are quite comparable, this could be due to the lessen
exposure of patient 1 to antibiotics. However, the bar plot showed a relative decrease in Firmicutes and
increase in Proteobacteria after his exposure to radiation (21.6 Gy)
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Table 3: Frequency of each phylum

Patient-1

Phylum

Patient-2

Patient-3

Controls

Pre

Mid

Pre

Mid

Last

Pre

Mid

Last

(1)

(2)

Actinobacteria

153

736

0

2

21

4

21

2

211

134

Bacteriodetes

3958

7093

4

12

25

0

0

192

628

9161

Firmicutes

22860

19888

38875

33170

25832

15960

1938

692

34990

26391

Fusobacteria

0

0

0

0

0

0

0

0

0

34

Proteobacteria

607

4554

598

773

8060

29542

66865

49113

7944

9821

Verrucomicrobia

0

0

0

0

0

0

0

0

0

2977

Bacteria
(unclassified)

79

63

0

0

0

0

0

0
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The

increase

in

bacterial

frequencies

in

the

presence

of

multiple broad spectrum antibiotic courses along with a high dose
(50.4 Gy) of directed gamma radiation at the pelvic region is an
abnormal phenomenon. Therefore, a higher resolution or an intuition
of more specificity to the bacterial taxa was needed. The frequency
table at the genus level was obtained for all samples from qiime2. The
search criteria for the specific increasing genera was set as follows: (1)
the frequency per patient is higher at each time point (fluctuating taxa
were excluded), (2) frequencies per taxa is elevated in the three
patients or completely absent in one patient. According to these
criteria, eight different genera were identified (Table-4), six of which
belong to the Firmicutes phylum (that had overall decreased): one
belongs to Proteobacteria and the last is a member of Bacteroidetes
phylum.
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Table 4: Constantly increasing bacterial genera

Genus

Patient-1

Patient-2

Patient-3

Controls

Pre

Mid

Pre

Mid

Last

Pre

Mid

Last

(1)

(2)

Bacteroides

5

23

0

7

22

0

0

192

20

20

Streptococcus

13

22

14

46

72

NA

NA

NA

535

286

Defluviitaleaceae*

127

478

0

98

467

NA

NA

NA

12

0

Dorea

28

309

57

97

135

NA

NA

NA

95

119

Subdoligranulum

309

1434

0

7

79

NA

NA

NA

1909

112

Ruminococcaceae*

1120

2575

6

237

368

NA

NA

NA

444

468

Clostridiales**

25

647

0

3

23

NA

NA

NA

1225

0

Escherichia-shigella

95

1117

598

549

7977

25630

66865

49113

3330

2087

*Family
**Order
NA: Not Available
Full taxonomic classification:
1. Bacteria; Bacteroidetes; Bacteroidia; Bacteroidales; Bacteroidaceae;
Bacteroides
2. Bacteria; Firmicutes; Bacilli; Lactobacillales; Streptococcaceae;
Streptococcus
3. Bacteria; Firmicutes; Clostridia; Clostridiales; Defluviitaleaceae;
uncultured
4. Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Dorea
5. Bacteria; Firmicutes; Clostridia; Clostridiales; Ruminococcaceae;
Subdoligranulum
6. Bacteria; Firmicutes; Clostridia; Clostridiales; Ruminococcaceae
7. Bacteria; Firmicutes; Clostridia; Clostridiales
8. Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
Enterobacteriaceae; Escherichia-Shigella
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Chapter 5: Discussion
The gut microbiota is now being linked to various aspects in
life rather than only its role in food digestion. It has been described as
the “forgotten organ”, owing to its diverse and effective roles (O’Hara
& Shanahan, 2006). The relationship between microbiota and cancer
has been intensively studied. Various links were created to describe
the role of microbiota in developing cancer at different body sites as
well as its role in determining the response to treatment, including
chemotherapy,

radiotherapy

or

immunotherapy

(Gerassy-Vainberg

et

al., 2018; Gopalakrishnan et al., 2018; Nam et al., 2013; Routy et al.,
2018; Viaud et al., 2013).
Crawford

and

colleagues

reported

that

the

GF

mice

are

resistant to high dose (16 Gy) of TBI (Crawford & Gordon, 2005).
The described resistance to TBI in GF mice was attributed to the role
of the microbiota in inducing severe intestinal inflammation

and

increasing Interleukin-1b, that result in tissue damage and might lead
to mice death. Several studies on human and mice models reported the
microbiota dysbiosis after radiotherapy directed to the pelvic region,
with a general decrease in Firmicutes and Bacteroidetes along with an
increase in Proteobacteria and overall decrease in alpha diversity
(Nam et al., 2013; Wang et al., 2015).
In the current observational study, we describe the effect of
directing radiotherapy to the pelvic region on the microbial alpha
diversity of infant cancer patients who were already on chemotherapy
along with intensive doses of various broad-spectrum antibiotics. In
comparison with two healthy controls; the patients’ alpha diversity
was generally lower. However, the extent of reduction was variable
among the patients in study. This can be attributed to the different
antibiotics courses prescribed for each, independent of the others.
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On the phylum level, Firmicutes decreased post radiation while
Proteobacteria

increased.

This

agrees

with

previously

described

dysbiosis after radiotherapy in adults (Nam et al., 2013; Wang et al.,
2015). Our results contradicted those by Nam and colleagues who
reported an elevation in the relative abundance of Actinobacteria in
gynecological cancer patients compared to healthy individuals (Nam
et al., 2013). In their study, they selected gynecological cancer patients
who did not take any antibiotics at the time of sample collection.
However, excluding antibiotics from infants’ treatment protocols was
not possible. Therefore, the variation observed might be attributed to
antibiotics.

Moreover,

by

comparing

actinobacterial

abundance

between patient-1 (at least 2 months between last antibiotic and point
zero collection), patients 2 and 3 (last antibiotic course was on the
same month of sample collection) we can find that Patient-1 has more
Actinobacteria.

In

general,

Patient-1

had

higher

alpha

diversity

(chao1: 104, Shannon: 3.121) that was comparable to the controls
(chao1: 111, 127 and Shannon: 3.18, 3.11 respectively). This could be
due to the long gap between the last antibiotic dose and point zero
collection time, since it was previously reported that the microbiota
can fully rebound in most patients after antibiotics courses within 90
days (Raymond et al., 2016).
By comparing the alpha diversity indices for each patient to
himself at the three sample collection points, we found that Patient-3
experienced a drop in alpha diversity post radiation and antibiotics. On
the contrary Patients 1 and 2 had surprisingly higher alpha diversity
post treatment. We further defined the taxa that were constantly
increasing at the three-time points and the three patients at the highest
resolution

that

could

be

inferred

from

the

sequencing

reads.

Accordingly, eight taxa were identified (Bacteroides, Streptococcus,
Defluviitaleaceae,
Clostridiales and
belongs

to

Dorea,

Subdoligranulum,

Escherichia-shigella).

Bacteroidetes

phylum
39

Except
and

Ruminococcaceae,
for

Bacteroides

Escherichia-shigella

that
that

belongs to Proteobacteria phylum, all remaining six taxa belong to
Firmicutes phylum that was generally decreasing.
When

ionizing

radiation

is

directed

to

the

targeted

body

location, it primarily disrupts the cellular macromolecules including
proteins, lipids and DNA resulting in mutations that might trigger the
DNA damage response pathways or activate one of the cellular death
mechanisms that include: apoptosis, autophagy or necrosis (Van Der
Kogel et al., 2009). The damaging effect of ionizing radiation on the
bacterial cells is reflected on DNA mutations as in

eukaryotes.

However, the radiosensitivity of bacteria differs greatly from one
bacterial species to another. Some bacterial species are known to be
radiosensitive,

while

others

are

extremely

radioresistant,

e.g.

Deinococcus radiodurans that can withstand up to 5000 Gy of gamma
irradiation (Slade et al., 2011). Goudarzi and colleagues studied the
effect of 12 Gy of X-ray irradiation on the gut microbiome of mice;
they

reported

an

increase

in

families

Lactobacillaceae

and

Staphylococcaceae while the Lachnospiraceae, Ruminococcaceae and
Clostridiacea

families

have

decreased

in

their

relative

abundance

(Goudarzi et al., 2016). Direct comparison between those reported
variations in relative abundance to the variations we have reported (all
five families were increasing in relative abundance post radiation) is
not rational because of the following reasons: (1) the reported changes
were due to low dose X-ray irradiation, while we used 50 Gy of
gamma irradiation, (2) our study was conducted in the presence of
antibiotics

and

chemotherapy,

which

both

affect

the

microbiota.

Raymond and colleagues have studied the effect of antibiotics on
microbiome using deep shotgun sequencing and reported the detection
of resistant genes post antibiotic treatment, that might have been
related to an increase in relative abundance of those species post
antibiotics

(Raymond

et

al.,

2016).

Accordingly,

what

could

be

inferred is the possible radiosensitivity of the fluctuating bacterial
families. Further studies are needed to confirm with reflection to the
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possible mutations in antibiotics resistant genes that might increase or
decrease the antibiotics sensitivity to the target bacteria.
In conclusion, the relationship between the gut microbiome
and cancer
relative

treatments is ultimately complicated.

abundance

Defluviitaleaceae,
Clostridiales and
reported

of

eight

Dorea,

taxa

fluctuation

in

(Bacteroides,

Subdoligranulum,

Escherichia-shigella)
the

same

The increase in

together
taxa

Streptococcus,

Ruminococcaceae,
with

the previously

might

indicate

their

radiosensitivity. However, further studies are needed to confirm. The
gut microbiota profile of the patients’ prior cancer treatment may
predict

the

response,

while

the

proper

manipulation

microbiome can improve the effect of cancer therapy.
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Appendix 1- Scripts
Qiime2-2017.12
#Generate OTU table (feature table), Assign Taxonomy (SILVA full
length) and generate the phylogenetic tree
#Import sequence files to Qiime2
#manifest phred33
#create a manifest file
#rename file names as in the manifest
qiime tools import --type 'SampleData[PairedEndSequencesWithQuality]'
--input-path pe-33-manifest --output-path paired-end-demux.qza -source-format PairedEndFastqManifestPhred33
#quality check
qiime demux summarize \
--i-data paired-end-demux.qza \
--o-visualization demux-summary-1.qzv
#The sequences are sorted inline from eurofins, sequences sorted by
barcode then trimmed.
#quality_filter
qiime quality-filter q-score \
--i-demux paired-end-demux.qza \
--o-filtered-sequences demux-filtered.qza \
--o-filter-stats demux-filter-stats.qza
#denoise_after_filtering
qiime deblur denoise-16S \
--i-demultiplexed-seqs demux-filtered.qza \
--p-trim-length 230 \
--o-representative-sequences rep-seqs-deblur.qza \
--o-table table-deblur.qza \
--p-sample-stats \
--o-stats deblur-stats.qza
mv rep-seqs-deblur.qza rep-seqs.qza
mv table-deblur.qza table.qza
#create qiime visualizations
qiime metadata tabulate \
--m-input-file demux-filter-stats.qza \
--o-visualization demux-filter-stats.qzv
qiime deblur visualize-stats \
--i-deblur-stats deblur-stats.qza \
--o-visualization deblur-stats.qzv
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#create a metadata file on google sheets and save as (.tsv)
#feature table and feature summary
qiime feature-table summarize \
--i-table table.qza \
--o-visualization table.qzv \
--m-sample-metadata-file sample-metadata.tsv
qiime feature-table tabulate-seqs \
--i-data rep-seqs.qza \
--o-visualization rep-seqs.qzv
#Generate a tree for phylogenetic diversity analyses
qiime alignment mafft \
--i-sequences rep-seqs.qza \
--o-alignment aligned-rep-seqs.qza
#mask or filter
qiime alignment mask \
--i-alignment aligned-rep-seqs.qza \
--o-masked-alignment masked-aligned-rep-seqs.qza
#create a phylogenetic tree
qiime phylogeny fasttree \
--i-alignment masked-aligned-rep-seqs.qza \
--o-tree unrooted-tree.qza
#taxonomy_silva_full_length
qiime feature-classifier classify-sklearn \
--i-classifier silva-119-99-nb-classifier.qza \
--i-reads rep-seqs.qza \
--o-classification taxonomy.qza
qiime metadata tabulate \
--m-input-file taxonomy.qza \
--o-visualization taxonomy.qzv
#bar_plot
qiime taxa barplot \
--i-table table.qza \
--i-taxonomy taxonomy.qza \
--m-metadata-file sample-metadata.tsv \
--o-visualization taxa-bar-plots.qzv
#export to biom hdf5
qiime tools export \
table.qza \
--output-dir exported-feature-table
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#export the following files to be used in R-phyloseq:
feature table in biom format
taxonomy (export as tsv)
re_seq_file.fasta
tree.nwk
metadata.tsv
#append taxonomy classification to feature table and convert to biom
format
biom add-metadata -i feature-table.biom -o table.w_omd.biom -observation-metadata-fp taxonomy.tsv --observation-header
OTUID,taxonomy --sc-separated taxonomy
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Usearch Script
#fastq_info_command_in_fq_directory
mkdir -p ../fastq_info
for fq in *.fastq
do
usearch -fastx_info $fq -output ../fastq_infotrim/$fq
done
#extract EE
cd ../fastq_infotrim
grep "^EE" *

#quality_chart
usearch -fastq_chars 16s_sample1_2_V3V5_FWD.fastq -log chars.log
#trimming_to_200bp
#Sample1

usearch -fastx_truncate 16s_sample1_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout PatA1_R1.fastq
#Sample2
usearch -fastx_truncate 16s_sample2_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout PatA2_R1.fastq
#sample3
usearch -fastx_truncate 16s_sample3_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout PatB1_R1.fastq
#sample4
usearch -fastx_truncate 16s_sample4_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout PatB2_R1.fastq
#sample5
usearch -fastx_truncate 16s_sample5_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout PatB3_R1.fastq
#sample6
usearch -fastx_truncate 16s_sample6_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout PatC1_R1.fastq
#sample7
usearch -fastx_truncate 16s_sample7_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout PatC2_R1.fastq
#sample8
usearch -fastx_truncate 16s_sample8_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout PatC3_R1.fastq
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#sample9
usearch -fastx_truncate 16s_sample9_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout Cont1_R1.fastq
#sample10
usearch -fastx_truncate 16s_sample10_2_V3V5_FWD.fastq -trunclen
200 -label_suffix _R1 -fastqout Cont2_R1.fastq
#Sample1_REV
usearch -fastx_truncate 16s_sample1_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout PatA1_R2.fastq
#sample2_REV
usearch -fastx_truncate 16s_sample2_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout PatA2_R2.fastq
#Sample3_REV
usearch -fastx_truncate 16s_sample3_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout PatB1_R2.fastq
#sample4_REV
usearch -fastx_truncate 16s_sample4_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout PatB2_R2.fastq
#sample5_REV
usearch -fastx_truncate 16s_sample5_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout PatB3_R2.fastq
#sample6_REV
usearch -fastx_truncate 16s_sample6_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout PatC1_R2.fastq
#sample7_REV
usearch -fastx_truncate 16s_sample7_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout PatC2_R2.fastq
#sample8
usearch -fastx_truncate 16s_sample8_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout PatC3_R2.fastq
#sample9
usearch -fastx_truncate 16s_sample9_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout Cont1_R2.fastq
#sample10_REV
usearch -fastx_truncate 16s_sample10_2_V3V5_REV.fastq -trunclen
200 -label_suffix _R2 -fastqout Cont2_R2.fastq
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#cat command to pool FWD and REV (applied to the 10 samples)
cat Cont1_R1.fq Cont1_R2.fq > Cont1_R.fq
#cat all reads in one file
cat samples.txt | while read sample ; do cat $sample"_R2.fq" | paste
- - - - | awk -v sample=$sample 'BEGIN {FS="\t"} {print
"@"sample"."NR"\n"$2"\n"$3"\n"$4;}' > $sample.fastq ; done
cat *.fastq > tmp
mv tmp merged.fq
#filter_sequences
usearch -fastq_filter merged.fq -fastq_maxee 1.0
filtered.fa -relabel Filt

-fastaout

#finding_uniques
usearch -fastx_uniques filtered.fa -sizeout -relabel Uniq -fastaout
uniques.fa
#Cluster_OTU
usearch -cluster_otus uniques.fa -otus otus.fa -relabel Otu
#OTU table
usearch -otutab merged.fq -otus otus.fa -otutabout otutab_raw.txt biomout otutab.json -mapout map.txt -notmatched unmapped.fa dbmatched otus_with_sizes.fa -sizeout
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